Pre-eclampsia is a condition that affects some pregnant women, usually during the second half of pregnancy after 20 weeks. Early signs of preeclampsia include high blood pressure and proteinuria. Pre-eclampsia and related hypertensive disorders of pregnancy affect approximately 5% of all births. Worldwide, 10 million women develop pre-eclampsia; with about 80 000 women dying from pre-eclampsia and related complications each year, such as eclampsia (seizures), stroke, and haemorrhage. Although the precise aetiology of pre-eclampsia has been a source of long-standing debate, overwhelming opinion attributes the development of pre-eclampsia to impaired placentation in early pregnancy. However, more recent evidence has demonstrated that placental histology is invariably normal in pre-eclampsia and that the majority of neonates born of pre-eclamptic mothers are either normal or larger in size than expected.
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1,2 These findings undermine the fundamental assertion that abnormal placental development is a primary aetiological factor for preeclampsia and have led researchers to seek alternative hypotheses. One emerging and biologically plausible theory is that pre-eclampsia occurs as a consequence of cardiovascular maladaptation to pregnancy (TED talk at: https://bit.ly/2JP0oNT). The findings that cardiovascular dysfunction precedes pre-eclampsia, cardiovascular signs predominate in the clinical syndrome, and that the risk of cardiovascular disease persists for several decades postpartum is compelling evidence for the cardiovascular origins of pre-eclampsia. [3] [4] [5] [6] The concept that placental dysfunction is secondary to a maternal disorder is not new when one considers the clinical similarities between pre-eclampsia and gestational diabetes--both pregnancy-specific conditions that are 'cured' by birth. 7 The cardiovascular origin of pre-eclampsia hypothesis continues to be of relevance when interpreting the conduct and outcome of the recently-published ASPRE trial in the New England Journal of Medicine. Researchers conducted a double-blind, placebo-controlled trial in 13 European centres, where 1776 women with singleton pregnancies identified to be at high-risk for preterm (birth before 37 weeks) pre-eclampsia, were randomized to receive either aspirin 150 mg per day or placebo from 11 weeks to 36 weeks of gestation. The study demonstrated that preterm pre-eclampsia occurred in 1.6% in the aspirin group, as compared with 4.3% in the placebo group--a 60% reduction in preterm pre-eclampsia (odds ratio: 0.38; 95% confidence interval: 0.20 to 0.74). Adherence to therapy was formally evaluated as good in 80% of the participants, with no demonstrable difference in the incidence of neonatal or maternal adverse outcomes in either arm of the study.
The ASPRE study has several implications for clinical practice. Identification of women as high-risk for pre-eclampsia is usually based on a checklist of maternal characteristics and medical history conferring increased risks for pre-eclampsia. The ASPRE study used an algorithm that combined known risk factors with mean arterial pressure, uterine artery pulsatility index (a peripheral waveform index) and serum placental growth factor (PlGF -a member of the VEGF angiogenic sub-family) taken at 11 weeks to 13 weeks' gestation. The use of this algorithm more than doubles the sensitivity for preterm pre-eclampsia to 82%, thereby making a compelling case for the routine implementation of this screening protocol. 9 It should be noted that the screening test utilizes cardiovascular markers and pre-eclampsia prophylaxis is achieved using a drug with established vascular effects. 10 These findings are all further support for the cardiovascular origin of pre-eclampsia. It has long been presumed by researchers interested in pre-eclampsia that defects of trophoblast (placental) development, motility, invasion, and function are intrinsic defects that then influence uterine perfusion by way of inadequate spiral (uterine) artery invasion and remodelling. A reexamination of this assumption reveals that either it is incorrect or that-uniquely in human biology-placental end organ tissue structure influences upstream vascular perfusion. Recent preliminary basic research supports the more likely scenario that primary impaired uterine perfusion may lead to inadequate trophoblast invasion and function.
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Further basic science research is required here to delineate whether placental findings and effects in pre-eclampsia are a primary phenomenon or secondary to impaired maternal perfusion of the placental bed. It is also remarkable that for a disease, which has been clinically recognized for over a century and with a significant human toll, no diagnostic test exists. The validation of an effective multi-modal ASPRE screening test in early pregnancy for pre-eclampsia also raises the possibility and hope that combining cardiovascular markers may provide a clinically valuable predictive or diagnostic test in later pregnancy. 12 Here, a basic science focus on identifying biomarkers that are biologically related to the cardiovascular origins of placental dysfunction is needed. Arguably, the largest burden of disease lies in the maternal postpartum legacy of pre-eclampsia. More recent epidemiological data demonstrate that the peak onset of chronic hypertension following pre-eclampsia occurs in the first 2-3 years following pregnancy--not decades later as previously presumed. 3 Indeed, preterm pre-eclampsia is a stronger risk factor than smoking for the development of stroke and other cardiovascular diseases in women. This finding is consistent with the data showing echocardiographic evidence of occult diastolic dysfunction in the majority normotensive women one year following a pregnancy complicated by preterm pre-eclampsia. 13 PlGF and soluble fms-like tyrosine kinase-1 (sFlt1) levels are deranged in pre-eclampsia and in the postpartum period the sFlt1:PlGF ratio is an independent predictor of LV remodelling in postpartum women. 12, 14 These markers seem to be mechanistically implicated in cardiovascular changes both in and outside pregnancy. Although the APSRE study demonstrated an undeniable and desirable benefit in pregnancy outcome, it remains to be determined whether aspirin therapy in women at high-risk of preterm pre-eclampsia will ameliorate the deleterious long-term maternal cardiovascular consequences of pregnancy.
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